

Fast ForwardSM

General Fund

This project is funded by Fast Forward, LLC, a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward connects university-based MS research with private-sector drug development and funds small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS.

<i>Primary Investigator</i> David Selwood Canbex Therapeutics Ltd. London, UK	<i>Project Title</i> The Pharmacology, Safety, Pharmacokinetics and Efficacy of VSN16 and its Enantiomers	<i>Amount to be Committed</i> £242,500
--	---	---

About the Company

Founded in 2005, Canbex Therapeutics Ltd is a developer of active compounds for the treatment of spasticity in Multiple Sclerosis and other neurological disorders. The company is a licensing vehicle for this breakthrough technology. Building on the expertise of its founders, Professor David Selwood and Professor David Baker, Canbex has assembled a highly experienced drug development team to progress these experimental compounds toward treating patients. The company is managed and supported by UCL Business PLC, the commercialization company for University College London. In addition to recent Fast Forward investment, other shareholders and investors include the Bloomsbury Bioseed Fund; Esperante; UCL Business PLC; and The Wellcome Trust.

Project Background & Goals

Spasticity is a common and often painful symptom of MS that involves feelings of stiffness, tightness or sudden movements caused by a wide range of involuntary muscle spasms. Many of the current treatments for spasticity can cause significant side effects, such as muscle weakness (flaccidity), sedation or mood alteration that can limit their application in MS.

Canbex has identified a drug candidate that alleviates muscle spasticity in mice with an MS-like disease. The molecule -- VSN16R – stimulates novel cell docking sites and relieves spasticity



Fast*▶*ForwardSM

General Fund

without causing side effects such as flaccidity, sedation or mood alteration, which can occur with current treatments. Now the team is completing toxicity studies in rats, one of the final steps before bringing this molecule to the point of clinical trials in people with MS who experience spasticity.

Support from Fast Forward for this project could help bring to the market an innovative symptomatic therapy for people with MS that has the potential to be as effective as current anti-spasticity medicines without the significant side effects.